Avantex Biotechnologies Inc.
  • About
    • Overview
    • Management & Directors
    • Disclaimer
  • Applications
    • Lung Cancer Application
      • – Lung Cancer Problem
      • – Lung Cancer in China
    • Eye-Care Application
    • MRI Application
    • Cannabis Applications
    • Published Research Papers
  • News
    • Industry News
    • Media Contact
  • Contact
    • Contact Information
  • Search
  • Menu Menu

News

Media Contact

Reporters interested in learning more about Avantex Biotechnology should contact:

Ullrich Schade
M: +1-604-644-4914
E: uschade@avantexbio.com

Nikita Chou
M:  +1-778-888 3892
E:  nchou@avantexbio.com

  • Industry News
  • Media Contact

INDUSTRY NEWS

  • Graphite Nanomaterials Reviewed for Role in Drug Delivery SystemsAugust 18, 2022 - 9:33 pm
  • Samsung invests $15 million in US biotech firm to develop core nanotechnology drug deliveryAugust 12, 2022 - 10:03 pm
  • Mesoporous silica nanoparticles: Possibilities in therapeutic developmentJuly 28, 2022 - 10:00 pm
  • How different cancer cells respond to drug-delivering nanoparticlesJuly 22, 2022 - 9:19 pm
  • What to Expect From the Launch of Cannabis Edibles in CanadaDecember 31, 2019 - 12:00 pm
  • New Cannabis Products to Follow Edibles LegalizationSeptember 5, 2019 - 12:00 pm

ABOUT
Overview
Management & Directors
Disclaimer

BIOTECH APPLICATIONS
Eye-Care Application
Lung Cancer Application
– Lung Cancer Problem
– Lung Cancer in China
Cannabis Applications
MRI Application
Research Papers

NEWS
Industry News
Media Contact

CONTACT
Contact Information

CONTACT
Nikita Chou, President
E: nchou@avantexbio.com
M: +1-778-888-3892

Ullrich Schade, VP Marketing
E: uschade@avantexbio.com
M: +1-604-644-4914

Branding by:
NextPhase Strategy

Scroll to top